First-in-human CROSSCHECK-001 study marks company’s entry into the clinic with novel T-Bolt™ T-cell engager (TCE) "Patients with relapsed or refractory myeloid malignancies urgently need new treatment ...
First-in-human CROSSCHECK-001 study marks company’s entry into the clinic with novel T-Bolt™ T-cell engager (TCE) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crossbow Therapeutics, Inc., a biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results